JP2020522259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522259A5 JP2020522259A5 JP2019566601A JP2019566601A JP2020522259A5 JP 2020522259 A5 JP2020522259 A5 JP 2020522259A5 JP 2019566601 A JP2019566601 A JP 2019566601A JP 2019566601 A JP2019566601 A JP 2019566601A JP 2020522259 A5 JP2020522259 A5 JP 2020522259A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- sequence
- synthetic
- vector
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033319 polynucleotide Proteins 0.000 claims 34
- 102000040430 polynucleotide Human genes 0.000 claims 34
- 239000002157 polynucleotide Substances 0.000 claims 34
- 239000013598 vector Substances 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 102100022641 Coagulation factor IX Human genes 0.000 claims 5
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 5
- 108010076282 Factor IX Proteins 0.000 claims 4
- 229960004222 factor ix Drugs 0.000 claims 4
- 230000008488 polyadenylation Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 208000032182 acquired hemophilia B Diseases 0.000 claims 1
- 230000002457 bidirectional effect Effects 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 229960000027 human factor ix Drugs 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022123665A JP2022159358A (ja) | 2017-05-31 | 2022-08-03 | 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用 |
| JP2024076788A JP2024097922A (ja) | 2017-05-31 | 2024-05-09 | 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512833P | 2017-05-31 | 2017-05-31 | |
| US62/512,833 | 2017-05-31 | ||
| PCT/US2018/035267 WO2018222792A1 (en) | 2017-05-31 | 2018-05-31 | Optimized human clotting factor ix gene expression cassettes and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022123665A Division JP2022159358A (ja) | 2017-05-31 | 2022-08-03 | 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522259A JP2020522259A (ja) | 2020-07-30 |
| JP2020522259A5 true JP2020522259A5 (OSRAM) | 2021-07-26 |
| JP7119009B2 JP7119009B2 (ja) | 2022-08-16 |
Family
ID=64456331
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566601A Active JP7119009B2 (ja) | 2017-05-31 | 2018-05-31 | 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用 |
| JP2022123665A Pending JP2022159358A (ja) | 2017-05-31 | 2022-08-03 | 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用 |
| JP2024076788A Pending JP2024097922A (ja) | 2017-05-31 | 2024-05-09 | 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022123665A Pending JP2022159358A (ja) | 2017-05-31 | 2022-08-03 | 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用 |
| JP2024076788A Pending JP2024097922A (ja) | 2017-05-31 | 2024-05-09 | 最適化されたヒト凝固第ｉｘ因子遺伝子発現カセットおよびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11530402B2 (OSRAM) |
| EP (1) | EP3630978A4 (OSRAM) |
| JP (3) | JP7119009B2 (OSRAM) |
| KR (2) | KR20240010098A (OSRAM) |
| CN (2) | CN114875051A (OSRAM) |
| AU (1) | AU2018275549B2 (OSRAM) |
| CA (1) | CA3064450A1 (OSRAM) |
| MX (2) | MX2019014379A (OSRAM) |
| WO (1) | WO2018222792A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| WO2021067389A1 (en) * | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| EP4051324A4 (en) * | 2019-10-28 | 2023-11-29 | University Of Florida Research Foundation, Incorporated | Gene therapy vectors |
| WO2021207077A1 (en) * | 2020-04-06 | 2021-10-14 | Homology Medicines, Inc. | Adeno-associated virus compositions for ids gene transfer and methods of use thereof |
| CN113817759B (zh) * | 2020-07-10 | 2023-06-02 | 南京吉迈生物技术有限公司 | 修饰的因子ix、组合物、方法及其在基因治疗中的应用 |
| CN115109788A (zh) * | 2021-03-23 | 2022-09-27 | 北京锦篮基因科技有限公司 | Aav介导的人脂蛋白脂酶肝脏异位表达载体及其用途 |
| US20240287490A1 (en) * | 2021-06-23 | 2024-08-29 | Inspirar Limited | Composition and method for treating hemophilia b |
| CN114277057B (zh) * | 2021-07-09 | 2023-10-13 | 上海天泽云泰生物医药有限公司 | 用于治疗或预防b型血友病的重组腺相关病毒载体和方法 |
| WO2023077012A1 (en) * | 2021-10-27 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for expressing factor ix for hemophilia b therapy |
| EP4509606A4 (en) * | 2022-04-19 | 2025-12-10 | Kanglin Biotech Hangzhou Co Ltd | CONSTRUCTION OF NUCLEIC ACID FOR THE TREATMENT OF AN INHERITED COAGULATION FACTOR DEFICIENCY AND ITS USE |
| CN115029360B (zh) * | 2022-05-30 | 2024-08-02 | 上海勉亦生物科技有限公司 | 用于治疗粘多糖贮积症iiia型的转基因表达盒 |
| CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
| WO2025143742A1 (ko) * | 2023-12-26 | 2025-07-03 | 삼성바이오에피스 주식회사 | 혈액응고인자 IX를 암호화하는 코돈-최적화된 폴리뉴클레오티드 및 이를 포함하는 rAAV 생산용 플라스미드 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2650838A1 (fr) * | 1989-08-09 | 1991-02-15 | Transgene Sa | Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu |
| CA2162497A1 (en) * | 1993-06-10 | 1994-12-22 | Sheila Connelly | Adenoviral vectors for treatment of hemophilia |
| DK2438931T3 (da) * | 2004-09-22 | 2013-12-02 | St Jude Childrens Res Hospital | Forbedret ekspression af faktor ix i genterapivektorer |
| US7943374B2 (en) * | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| EP2021499A4 (en) * | 2005-12-16 | 2010-02-17 | Univ Leland Stanford Junior | FUNCTIONAL ARRAYS FOR THE IDENTIFICATION OF ELEMENTS FOR GENE PRESSION REGULATION WITH HIGH THROUGHPUT |
| EP2037892B1 (en) * | 2006-06-19 | 2015-03-18 | Asklepios Biopharmaceutical, Inc. | Modified factor viii and factor ix genes and vectors for gene therapy |
| CN102628041B (zh) * | 2008-02-14 | 2013-09-11 | 财团法人牧岩生命工学研究所 | 适于表达用于基因治疗的编码序列的表达载体 |
| JP5797551B2 (ja) * | 2008-04-22 | 2015-10-21 | フエー・イー・ベー・フエー・ゼツト・ウエー | 肝特異的核酸調節要素ならびにその方法および用途 |
| US9700486B2 (en) * | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| RU2585532C2 (ru) * | 2014-01-31 | 2016-05-27 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук"(ФИЦ Биотехнологии РАН) | Плазмида для экспрессии рекомбинантного фактора свёртываемости крови ix человека, клетка сно - продуцент рекомбинантного фактора свёртываемости крови ix человека и способ получения указанного фактора |
| SI3116900T1 (sl) * | 2014-03-09 | 2021-02-26 | The Trustees Of The University Of Pennsylvania | Sestavki uporabni pri zdravljenju pomanjkanja ornitin transkarbamilaze(OTC) |
| KR102244434B1 (ko) * | 2014-08-11 | 2021-04-23 | 삼성전자주식회사 | 재조합 벡터 및 이를 이용한 목적 폴리펩타이드의 생산 방법 |
| GB201420139D0 (en) * | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| KR102554850B1 (ko) | 2015-02-06 | 2023-07-13 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 |
| CA2990193A1 (en) * | 2015-06-23 | 2016-12-29 | The Children's Hospital Of Philadelphia | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |
| CN108135845B (zh) * | 2015-09-18 | 2021-10-29 | Dnarx公司 | 用于体内核酸表达的系统和方法 |
| WO2017180861A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsulvania | Gene therapy for treating hemophilia b |
| CN106497949A (zh) * | 2016-10-14 | 2017-03-15 | 上海交通大学医学院附属瑞金医院 | 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用 |
| EP3600428A4 (en) * | 2017-03-23 | 2020-08-26 | Dnarx | SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO |
-
2018
- 2018-05-31 KR KR1020247001130A patent/KR20240010098A/ko not_active Ceased
- 2018-05-31 CA CA3064450A patent/CA3064450A1/en active Pending
- 2018-05-31 EP EP18809332.2A patent/EP3630978A4/en active Pending
- 2018-05-31 WO PCT/US2018/035267 patent/WO2018222792A1/en not_active Ceased
- 2018-05-31 AU AU2018275549A patent/AU2018275549B2/en active Active
- 2018-05-31 US US16/616,784 patent/US11530402B2/en active Active
- 2018-05-31 KR KR1020197036397A patent/KR102625470B1/ko active Active
- 2018-05-31 CN CN202210750672.9A patent/CN114875051A/zh active Pending
- 2018-05-31 CN CN201810547030.2A patent/CN108977452B/zh active Active
- 2018-05-31 JP JP2019566601A patent/JP7119009B2/ja active Active
- 2018-05-31 MX MX2019014379A patent/MX2019014379A/es unknown
-
2019
- 2019-11-29 MX MX2024007348A patent/MX2024007348A/es unknown
-
2022
- 2022-08-03 JP JP2022123665A patent/JP2022159358A/ja active Pending
- 2022-11-17 US US18/056,424 patent/US12209263B2/en active Active
-
2024
- 2024-05-09 JP JP2024076788A patent/JP2024097922A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522259A5 (OSRAM) | ||
| JP2020520662A5 (OSRAM) | ||
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| JP2015521465A5 (OSRAM) | ||
| HRP20231183T1 (hr) | Optimizirani gen faktora viii | |
| JP2018537089A5 (OSRAM) | ||
| JP2018520997A5 (OSRAM) | ||
| JP2019506166A5 (OSRAM) | ||
| JP2017512466A5 (OSRAM) | ||
| JP2021505133A5 (OSRAM) | ||
| JP2021501581A5 (OSRAM) | ||
| JP2019536462A5 (OSRAM) | ||
| JP2018506286A5 (OSRAM) | ||
| JP2014500724A5 (OSRAM) | ||
| JP2018522595A5 (OSRAM) | ||
| JP2016512683A5 (OSRAM) | ||
| JP2011004753A5 (OSRAM) | ||
| HRP20221089T1 (hr) | Optimizirani geni faktora viii | |
| JP2004512020A5 (OSRAM) | ||
| JP2013502226A5 (OSRAM) | ||
| JP2021505201A5 (OSRAM) | ||
| Ohmori et al. | New approaches to gene and cell therapy for hemophilia | |
| JP2021500922A5 (OSRAM) | ||
| JP2024041821A5 (OSRAM) | ||
| JP2017503505A5 (OSRAM) |